Alaway Eye Drops: New Product Launch Halted, Generating Millions

CHALLENGE When launched, Alaway, a new over-the-counter (OTC) allergy eye drop, would compete with 10 existing allergy eye drops and a dozen other allergy relief medicines which claimed to relieve itchy, red watery ‘allergy eyes’. The OTC market was dominated by deep-pocketed eye drop and pill allergy relief competitors - well-known brand names trusted and used by consumers for decades.

OPPORTUNITY Alaway’s formulation was the same as Novartis’ Zaditor, a hugely successful prescription-strength allergy eye drop which was coming off patent after many years. Alaway could be the first-to-market to claim prescription strength at an OTC price.

STRATEGY We developed the national marketing plan (including pricing, promotion and distribution) and used Nielsen’s BASES market research to forecast consumer interest and sales volume at various price points and levels of marketing spend.

RESULTS Consumer response to the product, packaging and campaign concepts was highly positive. But at approved price points and marketing spend levels the sales forecast was lower than expected, and the board deemed ROI sluggish. Within a few months the owners successfully sold all of the Alaway IP to Bausch & Lomb in a lucrative eight-figure deal. Within a year Bausch & Lomb successfully launched Alaway, where it successfully sells online and on retail shelves today.

WSC (WRAY SMART CREATIVE) MARKET (CUSTOMER & COMPETITIVE) RESEARCH l POSITIONING l BRAND & MESSAGE STRATEGY | CONTENT & CREATIVE DEVELOPMENT | MEDIA & DISTRIBUTION PLANNING